Molecular dynamics simulations and docking studies on 3D models of the heterodimeric and homodimeric 5-HT2A receptor subtype

Future Medicinal Chemistry

Volumn 3, Issue 6, 2011, Pages 665-681

  Bruno, Agostino ^a   Beato, Claudia ^a   Costantino, Gabriele ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2 RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CHEMOKINE RECEPTOR CXCR4; DOPAMINE 3 RECEPTOR; HETERODIMER; HOMODIMER; MONOMER; RECEPTOR SUBTYPE; RHODOPSIN; SEROTONIN 2A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR;

ARTICLE; CLUSTER ANALYSIS; DIMERIZATION; DRUG RECEPTOR BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; PROTEIN TARGETING; RECEIVER OPERATING CHARACTERISTIC; SIMULATION; THREE DIMENSIONAL IMAGING;

ANIMALS; BINDING SITES; CATTLE; CLUSTER ANALYSIS; DIMERIZATION; HUMANS; MOLECULAR DYNAMICS SIMULATION; PROTEIN ISOFORMS; PROTEIN STRUCTURE, QUATERNARY; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

EID: 79955965790     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.27     Document Type: Article

References (48)

1. Milligan G. The role of dimerisation in the cellular trafficking of G-protein-coupled receptors. Curr. Opin. Pharmacol. 10(1), 23-29 (2010).
2. Albizu L, Cottet M, Kralikova M et al. Time-resolved FRET between GPCR ligands reveals oligomeric in native tissues. Nat. Chem. Biol. 6(8), 587-594 (2010).
3. Prezeau L, Rives ML, Comps-Agrar L, Maurel D, Kniazeff J, Pin JP. Functional crosstalk between GPCRs: with or without oligomerization. Curr. Opin. Pharmacol. 10(1), 6-13 (2010).
4. Wu B, Chien EY, Mol CD et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330(6007), 1066-1071 (2010).
5. Simpson LM, Taddese B, Wall ID, Reynolds CA. Bioinformatics and molecular modelling approaches to GPCR aligomerization. Curr. Opin. Pharmacol. 10(1), 30-37 (2010).
6. Smith NJ, Milligan G. Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol. Rev. 62(4), 701-725 (2010).
7. Gonzàlez-Maeso J, Yuen T, Ebersole B et al. Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytriptamine 2A receptor agonist effects in mouse somatosensory cortex. J. Neurosci. 23(26), 8836-8843 (2003). (Pubitemid 37210895)
8. Parrish JC, Braden MR, Gundy E, Nichols DE. Differential phospholipase C activation by phenylalkylamine serotonin 5-HT2A receptor agonists. J. Neurochem. 95(6), 1575-1584 (2005). (Pubitemid 41804055)
9. 2A receptor-mediated signaling pathways to affect behavior. Neuron. 53(3), 439-452 (2007). (Pubitemid 46161267)
10. González-Maeso J, Sealfon SC. Agonist-trafficking and hallucinogens. Curr. Med. Chem. 16(8), 1017-1027 (2009).
11. Gonzalez-Maeso J, Ang RL, Yuen T et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature. 452(7183), 93-97 (2008). (Pubitemid 351355090)
12. Gonzalez-Maeso J, Sealfon SC. Psychedelics and schizophrenia. Trends Neurosci. 32(4), 225-232 (2009).
13. Brea J, Castro M, Giraldo J et al. Evidence for distinct antagonist-revealed functional states of 5-hydroxytryptamine(2A) receptor homodimers. Mol. Pharmacol. 75(6), 1380-1391 (2009).
14. Rovira X, Vivó M, Serra J, Roche D, Strange PG, Giraldo J. Modelling the interdependence between the stoichiometry of receptor oligomerization and ligand binding for a coexisting dimer/tetramer receptor system. Br. J. Pharmacol. 156(1), 28-35 (2009).
15. McRobb FM, Capuano B, Crosby IT et al. Homology Modeling and docking evaluation of aminergic G protein-coupled receptors. J. Chem. Inf. Model. 50(4), 626-637 (2010).
16. Selent J, Lopez L, Sanz F, Pastor M. Multi-receptor binding profile of clozapine and olonzapine: a structural study based on the new beta2 adrenergic receptor template. ChemMedChem 3(8), 1194-1198 (2008).
17. 2A complex. An atomistic resolution study of a potential new target in psychiatric conditions. J. Chem. Inf. Model. 49(6), 1602-1616 (2009).
18. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J. Mol. Graph. 14(1), 33-38 (1996). (Pubitemid 26152973)
19. Shao J, Tanner SW, Thompson N, Cheatham TE III. Clustering molecular dynamics trajectories: 1. Characterizing the performance of different clustering algorithms. J. Chem. Theory Comput. 3(6), 2312-2334 (2007).
20. Vaidehi N. Dynamics and flexibility of G-protein-coupled receptor conformations and their relevance to drug design. Drug Discov. Today 15(21-22), 951-957 (2010).
21. Amaro R, Baron R, McCammon JA. An improved relaxed complex scheme for receptor flexibility in computer-aided drug design. J. Comput. Aided Mol. Des. 22(9), 693-705 (2008).
22. Mobarec JC, Filizola M. Advanced in the development and application of computational methodologies for structural modeling of G-protein coupled receptors. Expert Opin. Drug Discov. 3(3), 343-355 (2008). (Pubitemid 351425377)
23. Totrov M, Abagyan R. Flexible ligand docking to multiple receptor conformations: a practical alternative. Curr. Opin. Struct. Biol. 18(2), 178-184 (2008).
24. 2receptor from a human to a rat pharmacology. FEBS Lett. 307(3), 324-328 (1992).
25. Roth BL, Shoham M, Choudhary MS, Khan N. Identification of conserved residues essential for agonist binding and second messenger production at 5-hydroxytriptamine2A receptors. Mol. Pharmacol. 52(2), 259-266 (1997). (Pubitemid 27349617)
26. Roth BL, Willins DL, Kristiansen K, Kroeze WK. 5-hydroxytryptamine2- family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol. Ther. 79(3), 231-257 (1998). (Pubitemid 28393877)
27. Shapiro DA, Kristiansen K, Kroeze WK, Roth BL. Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol. Pharmacol. 58(5), 877-886 (2000).
28. Kristiansen K, Kroeze WK, Willins DL et al. A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism. J. Pharmacol. Exp. Ther. 293(3), 735-746 (2000).
29. Ebersole BJ, Visiers I, Weinstein H, Sealfon SC. Molecular basis of partial agonism: orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy. Mol. Pharmacol. 63(1), 36-43 (2003). (Pubitemid 36043806)
30. 2Areceptor. Mol. Pharmacol. 72(5), 1200-1209 (2007). (Pubitemid 350012594)
31. Blaazer AR, Smid P, Kruse CG. Structure- activity relationship of phenylalkylamines as agonist ligand for 5-HT2A receptors. ChemMedChem. 3(9), 1299-1309 (2008).
32. Ballestreros JA, Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein coupled receptors. Methods Neurosci. 25, 366-428 (1995).
33. Okuno Y, Tamon A, Yabuuchi H et al. GLIDA: GPCR-ligand database for chemical genomics drug discovery - database and tools update. Nucleic Acids Res. 6(Suppl. 1) D907-D912 (2008). (Pubitemid 351149843)
34. Rabin RA, Regina M, Doat M, Winter JC. 5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens. Pharmacol. Biochem. Behav. 72(1-2), 29-37 (2002). (Pubitemid 34251305)
35. 2, receptor subtypes. J. Pharmacol. Exp. Ther. 303(2), 815-822 (2002). (Pubitemid 35231258)
36. 2Creceptors. Naunyn Schmiedebergs Arch. Pharmacol. 359(1), 1-6 (1999). (Pubitemid 29142561)
37. Knight AR, Misra A, Quirk K et al. Pharmacological characterisation of the agonist radioligand binding site of 5-HT2A, 5-HT2B and 5-HT2C receptors. Naunyn Schmiedebergs Arch. Pharmacol. 370(2), 114-123 (2004). (Pubitemid 39222863)
38. Seeman P, Kapur S. Atypical antipsychotics. Mechanism of action. Br. J. Psychiatry. 180, 465-466 (2002).
39. Cussac D, Boutet-Robinet E, Ailhaud MC et al. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C- VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur. J. Pharmacol. 594(1-3), 32-38 (2008).
40. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors - focus on newer generation compounds. Life Sci. 68(1), 29-39 (2000).
41. Friesner RA, Banks JL, Murphy RB et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47(7), 1739-1749 (2004). (Pubitemid 38380917)
42. Rasmussen SGF, Choi H-J, Fung JJ et al. Structure of a nanobody-stabilized active state of the β2-adrenoceptor. Nature 469(7329), 175-180 (2011).
43. Rosembaum DM, Zhang C, Lyons JA et al. Structure and function of an irreversible agonist- β2-adrenoceptor complex. Nature 469(7329), 236-240 (2011).
44. Warne T, Moukhametzianov R, Baker JC et al. The structural basis for agonist and partial agonist action on a b1-adrenergic receptor. Nature 469(7329), 241-244 (2011).
45. Chien EY, Liu W, Zhao Q et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330(6007), 1091-1095 (2010).
46. Sonego P, Kocsor A, Pongor S. ROC analysis: applications to the classification of biological sequences and 3D structures. Brief. Bioinformatics 9(3), 198-209 (2008). (Pubitemid 351637942)
47. Reggio PH. Computational methods in drug design: modeling G protein-coupled receptor monomers, dimers, and oligomers. AAPS J. 8(2), E322-336 (2006).
48. Lagerstrom MC, Schioth HB. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7(4), 339-357 (2008).